Regolamentazione e diritto · 30/10/20261 min di lettura
Schedules of Controlled Substances: Placement of Centanafadine in Schedule III
Traduzione automatica locale · Lingua originale della fonte
Riepilogo
On July 24, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder in adults and…